Henry Schein, Inc.

Henry Schein, Inc. (HSIC) Market Cap

Henry Schein, Inc. has a market capitalization of $9.77B.

Price: $85.75

0.58 (0.68%)

Market Cap: 9.77B

NASDAQ · time unavailable

CEO: Frederick Lowery

Sector: Healthcare

Industry: Medical - Distribution

IPO Date: 1995-11-03

Website: https://www.henryschein.com

Henry Schein, Inc. (HSIC) - Company Information

Market Cap: 9.77B|Sector: Healthcare

Company Profile

Henry Schein, Inc. (HSIC) is a global leader in delivering a comprehensive suite of healthcare products and services. The company caters to a diverse clientele across the globe, including dental professionals and laboratories, physician practices, governmental entities, and various institutional and alternative healthcare facilities. Its operations are organized into two principal segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution division supplies an extensive array of dental goods, encompassing consumables (such as infection control items, impression materials, composites, anesthetics, and artificial teeth), specialized tools and equipment (like handpieces, dental chairs, delivery units, X-ray machinery, and advanced digital restoration systems), and personal protective equipment. This segment also provides essential equipment repair services. Furthermore, it distributes a broad range of medical supplies, including pharmaceuticals (both branded and generic), vaccines, surgical instruments, diagnostic kits, infection prevention solutions, imaging products, equipment, and nutritional supplements. The Technology and Value-Added Services segment focuses on empowering practices with advanced software, technology, and supplementary solutions. This includes specialized practice management software systems tailored for both dental and medical professionals. Beyond software, it delivers crucial value-added practice support services, such as non-recourse financial assistance, electronic services, comprehensive technology and network infrastructure support, hardware services, ongoing professional development programs, and expert consulting. Established in 1932, Henry Schein, Inc. maintains its corporate headquarters in Melville, New York.

Analyst Sentiment

70%
Buy

From 17 Active Polls

1Y Forecast: $87.63

▲ +2.2% Potential Upside

Consensus Target Metrics

Low Bound

$64

Median

$88

High Bound

$100

Average

$88

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$87.63
▲ +2.19% Upside
Low Target
$64.00
-25% Risk
Median Target
$88.00
3% Mid
High Target
$100.00
17% Max
Consensus
Buy
15 / 33 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 28, 2026Dec 27, 2025Sep 27, 2025Jun 28, 2025Mar 29, 2025Dec 31, 2024Sep 28, 2024Jun 29, 2024
Market Cap ($M)9,7688,2878,9357,9438,9348,4948,6169,2358,191
Enterprise Value ($M)13,37911,89812,46611,24812,14711,59111,36412,10110,891
Price to Earnings Ratio (P/E)25.6719.3822.1319.6625.8019.2823.0723.1719.78
Price/Earnings-to-Growth Ratio (PEG)7.546.4311.3543.0719.12
Price to Sales Ratio (P/S)0.732.462.602.382.762.682.702.912.61
Price to Book Ratio (P/B)3.022.542.752.362.592.572.542.642.33
Price to Free Cash Flow Ratio (P/FCF)22.66-60.9326.4356.33101.52-1415.5954.1978.9333.03
Enterprise Value to Sales (EV/Sales)3.533.633.373.753.663.563.813.47
Enterprise Value to EBITDA (EV/EBITDA)13.3546.4848.6944.1151.6945.8147.9551.2745.76
Debt to Equity Ratio3.601.151.141.020.970.970.850.850.81

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 HENRY SCHEIN INC (HSIC) — Investment Overview

🧩 Business Model Overview

Henry Schein operates primarily as a focused healthcare distribution and service platform, serving dental and medical practitioners and organizations. The company sources products from manufacturers, manages procurement and logistics, and supplies customers through an extensive delivery network and digital ordering channels. In parallel, it provides practice-oriented software, services, and IT-enabled offerings that support clinical workflows, purchasing, inventory management, and billing-related administrative needs.

This structure creates a “product + workflow” proposition: purchasing is supported by reliable fulfillment and product availability, while recurring services increase operational integration inside the customer’s practice. Over time, the combined procurement and software stack reduces the practical ability for customers to switch away without cost and disruption.

💰 Revenue Streams & Monetisation Model

Revenue is generated from (1) distribution of dental and medical consumables and equipment, and (2) services and software tied to practice operations. Distribution revenue is largely transactional (volume-driven), while services/software can be more recurring (seat/license and service-type arrangements).

Key margin drivers include:

  • Product mix and contract economics: gross margin varies with categories, purchasing terms, and the blend between consumables, specialty products, and equipment.
  • Operating leverage: scale in procurement and distribution can spread fixed costs across a larger order base.
  • Services attach and renewal rates: practice management and IT-related revenues tend to be less sensitive to day-to-day ordering volumes, supporting steadier profitability.
  • Working-capital discipline: inventory and payables/receivables management influence free cash flow quality in distribution-led models.

🧠 Competitive Advantages & Market Positioning

HSIC’s moat is strongest in switching costs and cost advantages from scale and logistics, reinforced by an integrated ecosystem around customer purchasing and practice operations.

  • High switching costs (workflow integration): customers that rely on HSIC’s ordering systems, fulfillment cadence, and practice support tools face operational friction in changing vendors, catalog formats, ordering workflows, and IT integrations.
  • Scale purchasing and distribution efficiency: procurement volume and supplier relationships support better unit economics and category coverage, improving competitiveness versus smaller distributors.
  • Logistics and service reach: delivery performance, catalog breadth, and service responsiveness matter in healthcare supply chains, especially for time-sensitive clinical operations.

Competitive benchmarking (primary peers):

  • McKesson and Cardinal Health: both are large, broad healthcare distributors with extensive distribution platforms. Their scale can be formidable, but their industry focus is more diversified across channels, including large-acuity and hospital-centric flows.
  • Patterson Companies: a key dental-focused distributor and services provider. The competitive set is most direct where customer mix, dental category breadth, and practice-technology offerings intersect.

HSIC’s differentiation centers on a more concentrated emphasis on dental and practice-oriented solutions, enabling tighter integration between purchasing, service support, and software-enabled workflows compared with more generalist distribution models.

🚀 Multi-Year Growth Drivers

Growth over a 5–10 year horizon is supported by healthcare demand trends and the monetization of workflow digitization in outpatient settings:

  • Outpatient and specialty utilization growth: steady demand for dental and preventive care supports long-run product consumption.
  • Clinical practice modernization: digitized practice workflows and IT-supported administration expand the services/software revenue pool.
  • Category expansion and higher-value mixes: growth in specialty dental products, consumables, and certain equipment categories can lift revenue per customer.
  • Market share capture through execution: customers often value service reliability and comprehensive ordering. Strong execution supports retention and incremental penetration.
  • Customer base rationalization: industry consolidation among providers can create opportunities for larger distributors and integrated service platforms to win accounts.

TAM expansion is driven both by demographic-linked demand (especially dental) and by the gradual shift toward higher-attached services and technology that increase revenue durability versus purely transactional distribution.

⚠ Risk Factors to Monitor

  • Pricing and reimbursement pressure on customers: customer economics influence order frequency and mix, affecting distribution volume and gross margin.
  • Vendor and category concentration: supplier terms and product availability can materially affect unit economics and service levels.
  • Working-capital volatility: inventory management and payables/receivables dynamics are central to cash flow in distribution businesses.
  • Regulatory and compliance exposure: healthcare distribution entails heightened compliance requirements (anti-fraud, contracting rules, and regulated handling practices).
  • Technology, cybersecurity, and operational resilience: software-enabled ordering and practice solutions increase the importance of secure systems and uptime.
  • Competitive intensity: large peers with broad footprints and strong pricing power can pressure margins, especially in commoditized product categories.

📊 Valuation & Market View

The market typically values healthcare distribution and services through a combination of EV/EBITDA and earnings-based multiples, with incremental value attributed to services/software durability via higher-quality earnings and improved cash flow stability. Key valuation drivers usually include:

  • Operating margin sustainability: evidence of gross margin resilience and controlled operating expense growth.
  • Mix shift toward recurring services: higher attach rates and service renewals can support steadier profitability.
  • Free cash flow conversion: working-capital discipline is often a differentiator versus peers.
  • Return on invested capital (ROIC): distribution models reward efficiency and capital discipline.

Because the business blends transactional distribution with services/software, investors generally underwrite both demand durability and the ability to sustain economics through category mix and operational leverage.

🔍 Investment Takeaway

HSIC’s long-term investment case rests on a structural combination of switching costs from integrated ordering/workflow relationships, scale-driven cost advantages in procurement and logistics, and an ecosystem approach that supports more durable services revenue. While competition from large diversified distributors and other dental-focused players is ongoing, HSIC’s emphasis on dental/practice integration and execution-backed fulfillment tends to reinforce retention and monetization over time.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for HSIC.

businesswire.com2026-07-30

Henry Schein Announces Leadership Transitions

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced today that it is creating the Henry Schein Leadership Team (HSLT) to replace its Executive Management Committee. The Company will also integrate its global supply chain organization with its global distribution group. The new leadership structure will continue to develop the Company's strategic priorities, accelerate its execution, and enhance enterprise collaboration. “I am pleased to announce a new leadership structu.

zacks.com2026-07-28

Henry Schein Prepares to Report Q2 Earnings: What's in the Cards?

HSIC heads into Q2 earnings with expectations for revenue and EPS growth as dental, specialty products and AI-enabled technology remain in focus.

defenseworld.net2026-07-24

Henry Schein, Inc. $HSIC Shares Sold by California Public Employees Retirement System

California Public Employees Retirement System cut its holdings in shares of Henry Schein, Inc. (NASDAQ: HSIC) by 14.9% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 246,925 shares of the company's stock after selling 43,137 shares during the

zacks.com2026-07-23

Are Investors Undervaluing Henry Schein (HSIC) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

businesswire.com2026-07-21

Henry Schein to Webcast Second Quarter 2026 Conference Call on Tuesday, August 4, 2026, at 8:00 a.m. ET

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its second quarter 2026 financial results before the stock market opens on Tuesday, August 4, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Fred Lowery, Chief Executive Officer and.

zacks.com2026-07-20

Will Henry Schein (HSIC) Beat Estimates Again in Its Next Earnings Report?

Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com2026-07-14

Zacks Industry Outlook McKesson, Cardinal, West Pharmaceutical, Align and Henry

McKesson, Cardinal, West Pharmaceutical, Align and Henry have been highlighted in this Industry Outlook article.

zacks.com2026-07-13

5 Medical Supply Stocks to Buy Amid Strong Industry Tailwinds

Here, we highlight five dental supplies stocks, MCK, CAH, WST, ALGN and HSIC, which are well positioned to generate wealth for investors amid improving industry prospect.

zacks.com2026-07-07

Is Henry Schein (HSIC) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

prnewswire.com2026-06-30

GoTu and Henry Schein Announce Strategic Partnership to Strengthen Dental Workforce Support Nationwide

MIAMI, June 30, 2026 /PRNewswire/ -- GoTu Technology, the nation's leading dental talent marketplace, and Henry Schein, Inc. (Nasdaq: HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced a new strategic partnership designed to help dental practices address ongoing staffing challenges and maintain continuity of patient care. Through this collaboration between GoTu and Henry Schein Dental Recruitment Services (a division of Henry Schein Financial Enterprises, LLC, a wholly-owned subsidiary of Henry Schein), dental practices will gain expanded access to GoTu's technology-enabled platform, which connects offices with qualified dental hygienists, dental assistants, and associate dentists for both temporary and permanent staffing needs.

zacks.com2026-06-23

Why Henry Schein (HSIC) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

seekingalpha.com2026-06-21

Henry Schein: Smile Because The Upside Isn't Over

Henry Schein remains a dominant global provider in dental and medical practitioner supplies, with strong market shares and ongoing revenue growth. HSIC's Q1 2026 revenue grew 6.3% year-over-year, driven by robust global dental merchandise and equipment demand, particularly in aging and expanding populations. Profitability metrics are mixed, but adjusted net income and EBITDA are rising; management guides for 3–5% revenue growth and mid-single-digit EBITDA growth in 2026.

benzinga.com2026-06-11

This Henry Schein Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

247wallst.com2026-06-11

Here Are Thursday’s Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, Toast, and More

Pre-Market Stock Futures: Futures are trading higher after a dreadful day on Wall Street, when all the major indices traded lower, and we saw the same pattern that has developed over the last week. The "Buy the Dip" traders come in, briefly get an uptick, and a move higher, and the sellers swarm in to... Here Are Thursday's Best Wall Street Analyst Research Calls: Callaway Golf, Chewy, CME Group, Danaher, General Dynamics, Intel, SpaceX, Rocket Lab, Toast, and More

zacks.com2026-06-04

Why Is Henry Schein (HSIC) Up 4.6% Since Last Earnings Report?

Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-28

"HSIC (2026-03-28, Q1) reported revenue of $3.37B and net income of $107M. EPS was $0.93 (diluted $0.92). On a YoY basis, revenue increased +6.3% (from $3.168B in 2025-03-29) while net income decreased slightly by -2.7% (from $110M). QoQ, revenue declined -2.0% (from $3.437B in 2025-12-27) and net income rose +5.9% (from $101M). Profitability was mixed: gross margin expanded to 31.8% vs 29.1% in Q4, and net margin improved to 3.18% vs 2.94% QoQ; however, net margin was slightly below YoY levels (3.47% in Q1 2025), consistent with the modest YoY net income slip. Cash flow weakened materially in the quarter: operating cash flow was -$97M and free cash flow was -$136M, driven primarily by a large working-capital use (change in working capital of -$278M). Despite negative near-term cash generation, balance sheet leverage appears stable for a non-bank: total assets rose to $11.3B (+0.8% QoQ), while total equity was steady at $4.82B (+0.6% QoQ). The company reduced cash (to $138M) and appears to have continued shareholder returns via buybacks (repurchased -$125M); dividends were $0 in the provided data. Total shareholder return is supported by strong momentum: the stock is up +24.55% over 1Y."

Revenue Growth

Positive

Revenue +6.3% YoY, but -2.0% QoQ from Q4, indicating growth with some quarter-to-quarter volatility.

Profitability

Neutral

Net income -2.7% YoY, but operating/net margins improved QoQ (net margin 3.18% vs 2.94%). Gross margin also expanded QoQ (31.8% vs 28.9%).

Cash Flow Quality

Neutral

Operating cash flow was -$97M and free cash flow -$136M in the quarter, mainly due to working-capital outflows (change in working capital -$278M). Buybacks continued.

Leverage & Balance Sheet

Positive

Total assets up to $11.3B (+0.8% QoQ) and equity stable at $4.82B (+0.6% QoQ). Debt is elevated (net debt $3.61B) but appears consistent rather than deteriorating sharply QoQ.

Shareholder Returns

Good

Strong market momentum: +24.55% 1Y. Buybacks of -$125M supported capital returns; dividends were $0 in the dataset.

Analyst Sentiment & Valuation

Positive

Current price ($78.83) vs consensus target ($85.43) implies modest upside (~+8%). High valuation multiples (e.g., P/E ~19) suggest the market is pricing in durable earnings.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Henry Schein delivered steady revenue growth in Q1 2026 ($3.4B, +6.3% YoY) with a notable margin improvement profile. GAAP operating margin fell 12 bps YoY to 5.41%, but non-GAAP operating margin rose 28 bps to 7.53%. Gross margin expanded 25 bps YoY and 86 bps sequentially, with management explicitly linking it to ongoing value creation execution (value pricing, corporate brand mix outperformance, and supplier cost discipline), suggesting early persistence rather than a transient benefit. The quarter also included a meaningful but non-core $11M remeasurement gain from increasing control of S.I.N. 360, with additional integration-related gains expected only in 2H 2026. Headwinds were concentrated in medical respiratory diagnostics tied to a light flu season (15%-20% of medical business), and premium implant weakness/flatness (more visible in the U.S.). Guidance maintains 2026 sales growth of ~3%-5% and non-GAAP EPS of $5.23-$5.37, assuming oil-related cost increases can be mitigated.

AI IconGrowth Catalysts

  • Henry Schein One launches, including next-generation AI clinical workflow demonstrated at Thrive Live (Las Vegas); AI integrated into global practice management suite
  • Value implants momentum: high single-digit value implant growth; S.I.N. 360 controlling interest supports faster-growing value implant portfolio
  • Dentrix Ascend and Dentally cloud growth: Dentally cloud customers +25% YoY; now >13,000 Dentrix Ascend and Dentale subscribers

Business Development

  • Completed controlling interest transaction in S.I.N. 360 (U.S. distributor for S.I.N. Brazil value implant systems) to strengthen U.S. implant portfolio control and enable integration efficiencies
  • Exclusive supplier initiated opportunities supporting U.S. dental equipment growth (traditional + digital imaging categories)

AI IconFinancial Highlights

  • Global sales: $3.4B (+6.3% YoY); 2.5% local currency internal +3.1% FX +0.7% acquisitions
  • GAAP operating margin: 5.41%, down 12 bps YoY; non-GAAP operating margin: 7.53%, up 28 bps YoY
  • Non-GAAP EPS: $1.32 vs $1.15 prior year; GAAP EPS: $0.92 vs $0.88 prior year; FX added ~+$0.03 diluted EPS
  • Gross margin: +25 bps YoY and +86 bps sequentially vs Q4, attributed to value creation initiatives (value pricing), own brand outperformance and mix, plus improved supplier cost discipline
  • S.I.N. 360 remeasurement gain: $11M (~$0.07 EPS); additional reregimen gains not expected until 2H 2026
  • Medical decline driver: light flu season reduced demand for point-of-care diagnostic test products; category ~15%-20% of medical business; excluding this, medical sales growth would be mid-single digits

AI IconCapital Funding

  • Share repurchases: ~1.6M shares at average $77.64 for ~$125M in Q1 2026
  • Remaining authorized/available repurchases: ~$655M at quarter end
  • Operating cash flow: -$97M (seasonal year-end working capital normalization via accounts payable/accrual decreases); expectation that full-year operating cash flow exceeds net income

AI IconStrategy & Ops

  • Value creation initiatives ongoing: outsourced partner appointed to centralize/select back-office functions; benefits expected later in 2026
  • Strategic buyouts of minority partners in specialty products to unlock integration opportunities
  • Indirect procurement savings via leveraging scale advantage
  • Gross profit initiatives: value pricing and enhanced growth of corporate brands
  • Global e-commerce platform rollout (henryschein.com) to U.S. and Canadian lab customers; >80% of U.S. dental e-commerce sales already transacted via henryschein.com; complete U.S. rollout targeted by end of August

AI IconMarket Outlook

  • 2026 guidance (current continuing operations): sales growth ~3%-5% vs 2025
  • 2026 non-GAAP diluted EPS: $5.23-$5.37; assumed non-GAAP effective tax rate ~24%
  • Adjusted EBITDA expected to grow in mid-single digits vs 2025 adjusted EBITDA of $1.1B
  • Benefits from value creation weighted toward 2H 2026; remeasurement gains recognized in 2026 expected to be less than 2025

AI IconRisks & Headwinds

  • Oil-driven pressure: higher merchandise/freight costs noted; guidance assumes mitigation of rising oil costs and includes plans to protect margins (no quantified bps sensitivity provided)
  • Medical demand cyclicality: respiratory illness/flu season weakness reduced point-of-care diagnostic tests; category ~15%-20% of medical business
  • Premium implant softness: premium implant sales described as flat to down in the U.S. (and lower single digits to flat overall), potentially consumer pressure; improved growth expected as year progresses

Q&A: Analyst Interest

  • Gross margin drivers & persistence: Management attributed Q1 gross margin strength to early value-creation benefits (value pricing), faster/dynamic response to pricing environment, strong corporate brand mix, and improved supplier cost competitiveness; they implied benefits are ongoing rather than a one-quarter event while oil is being mitigated.
  • Oil/freight cost mitigation: Management said crude oil impacts freight costs; they avoid relying solely on fuel surcharges and price defaults. They described mitigation plans in guidance but did not give a numeric oil-to-margin rule, instead stating the guidance assumes mitigation up to a “tipping point.”
  • Specialty/implants demand cadence: On specialty, management said Q1 results were in line with expectations with timing of customer buys. They emphasized value implant high single-digit growth and expected improved specialty growth through the year. Premium implants were flat-to-down, especially in the U.S., but improved growth is expected as the year progresses.

Sentiment: MIXED

Note: This summary was synthesized by AI from the HSIC Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for HSIC.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (HSIC)

© 2026 Stock Market Info — Henry Schein, Inc. (HSIC) Financial Profile